Skip to content
Precision for Medicine
iStock-1500823492 (1)

Streamline Your Study Start Up with Precision

Kickstart your clinical trials with efficiency and expertise.
In today’s fast-paced clinical trial environment, initiating your study effectively is more critical than ever. Precision's approach to Study Start Up combines technological innovation, regulatory insight, and global expertise to optimize every phase of trial initiation, ensuring your study begins with the momentum needed to succeed.
iStock-1332002332 (1) (1)

Accelerating your clinical trial start up

Successful clinical trials begin with a well-executed study start up. By focusing on strategic site selection and swift regulatory submissions,  Precision’s global study start up team helps set the foundation for timely and successful trial outcomes. Our team delivers site activation with precision by leveraging locally dedicated staff and through close partnership with our Regulatory Affairs department. Through this synergy, we streamline submissions across North America, Europe, and Asia Pacific. Every study presents its own unique challenges therefore it's critical to work with seasoned staff dedicated to guiding effective study start up.
5 Average years of start up experience
45 countries supported by Precision’s Start Up team

Our Proven Pathway to Study Start Up Success

Precision's study start up services are built on a foundation of detailed planning and proactive strategy. From identifying the most suitable sites worldwide to navigating the complexities of local and global regulations, our team ensures your study is initiated without delay. With a focus on cross-functional collaboration, accountability, and proactive risk management, we partner with you to accelerate patients' access to life-changing therapies.
The Precision path

Expert perspectives from Precision

Gain new insights and strategies from our experts at the forefront of clinical and translational research.

Read: Receptor Occupancy in the Era of Multispecific Therapeutics Receptor Occupancy in the Era of Multispecific Therapeutics

Translational Research - Lab Services

Receptor Occupancy in the Era of Multispecific Therapeutics

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=159488778875, hs_child_table_id=0, hs_updated_at=1716454216458, hs_published_at=1785259834087, description=Pharma industry veteran and expert at biomarker-driven clinical trial design and execution. Leader of biomarker and drug development programs for pharmaceutical and diagnostics companies, as well as the National Institutes of Health. Spearheaded the discovery of pharmacodynamic biomarkers and novel targets for inflammatory disease therapy., avatar=Image{width=576,height=576,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/Headshots/Headshots%20no%20background/Deb%20Phippard.webp',altText='Deb Phippard',fileId=165892372605}, linkedin=https://www.linkedin.com/in/deb-phippard-103b54, team=[{id=163072475007, name='Precision for Medicine Leadership'}], hs_name=, hs_path=, lastname=Phippard, PhD, hs_initial_published_at=1775839468505, hs_created_at=1709645745106, hs_is_edited=false, hs_deleted_at=0, name=Deborah, job= Chief Scientific Officer, slug=deborah-phippard, email=, hs_updated_by_user_id=51739740}, second={hs_id=218178874459, hs_child_table_id=0, hs_updated_at=1785241362455, hs_published_at=1785259834087, description=Jenny Zilberberg has more than 20 years of combined experience across academia and biotechnology, with expertise in translational immunology, cancer immunotherapy, and biomarker strategy. Most recently, she served as Head of Research at Imvax, where she led preclinical development and biomarker activities for the company’s immunotherapy platform and lead glioblastoma program. At Precision, Jenny partners with sponsors to design and implement biomarker and bioanalytical solutions that support clinical development across oncology and autoimmune diseases., avatar=Image{width=480,height=480,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/JennyZilberberg.jpeg',altText='JennyZilberberg',fileId=218182303073}, lastname=Zilberberg, hs_initial_published_at=1785241367324, hs_created_by_user_id=65712240, hs_created_at=1785241302354, hs_is_edited=false, hs_deleted_at=0, name=Jenny, job=Vice President, Scientific Strategy, slug=Jenny-zilberberg, hs_updated_by_user_id=51739740}, third={}})
  • Deborah P. avatar

    Deborah P.

  • Jenny Z. avatar

    Jenny Z.

Discover
Read: Case Study: Prescreening Intel Restores Phase 3 Colorectal Enrollment Case Study: Prescreening Intel Restores Phase 3 Colorectal Enrollment

Case Study: Prescreening Intel Restores Phase 3 Colorectal Enrollment

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=217320686850, hs_child_table_id=0, hs_updated_at=1784229354065, hs_published_at=1785259834087, description=Erica Donnelly is a Senior Clinical Trial Manager with over 18 years of experience in the pharmaceutical and CRO industries. She has experience in Phase I-III clinical trials. She has experience in global vendor management and leading teams of CRAs and CTAs. Erica has oncology therapeutic experience including AML., avatar=Image{width=800,height=800,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/1604417210025.jpeg',altText='1604417210025',fileId=217303275102}, lastname=Donnelly, hs_initial_published_at=1784230182153, hs_created_by_user_id=65712240, hs_created_at=1784229139957, hs_is_edited=false, hs_deleted_at=0, name=Erica, job=Senior Clinical Trial Manager, slug=erica-donnelly, hs_updated_by_user_id=51739740}, second={}, third={}})
  • Erica Donnelly avatar

    Erica Donnelly

Discover
Read: Case Study: Theranostic Radiopharm Trial and Evolving FDA Expectations Case Study: Theranostic Radiopharm Trial and Evolving FDA Expectations

Case Study: Theranostic Radiopharm Trial and Evolving FDA Expectations

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=217320686763, hs_child_table_id=0, hs_updated_at=1784229018395, hs_published_at=1785259834087, description=Rachel Piacente is a Clinical Trial Manager at Precision for Medicine with over 15 years of clinical research experience. She specializes in oncology, hematology, cell and gene therapy, CAR-T, radiopharmaceuticals, and multinational Phase I–IV trials. Rachel has proven expertise in trial operations, site management, regulatory compliance, budgeting, vendor oversight, and cross-functional team leadership across US and global studies., avatar=Image{width=1010,height=1305,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/Rachel%20Piacente_pic.jpg',altText='Rachel Piacente_pic',fileId=217303397279}, lastname=Piacente, hs_initial_published_at=1784230182153, hs_created_by_user_id=65712240, hs_created_at=1784228917126, hs_is_edited=false, hs_deleted_at=0, name=Rachel, job=Clinical Trial Manager , slug=rachel-piacente, hs_updated_by_user_id=51739740}, second={hs_id=217314606343, hs_child_table_id=0, hs_updated_at=1784229356581, hs_published_at=1785259834087, description=Jennifer Coates is a Project Manager at Precision for Medicine with over a decade of clinical research experience supporting global clinical trials across multiple phases of development and a broad spectrum of therapeutic areas. She specializes in driving the successful execution of theranostic and other complex clinical programs, providing operational leadership to cross-functional teams while ensuring compliance with regulatory requirements and quality standards. Jennifer is known for fostering strong partnerships with sponsors and study teams, enabling collaboration, operational excellence, and the production of high-quality project deliverables., avatar=Image{width=2185,height=3261,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/JenCoates.jpeg',altText='JenCoates',fileId=217308893107}, lastname=Coates, hs_initial_published_at=1784230182153, hs_created_by_user_id=65712240, hs_created_at=1784228926906, hs_is_edited=false, hs_deleted_at=0, name=Jennifer, job=Project Manager, slug=jennifer-coates, hs_updated_by_user_id=51739740}, third={}})
  • Rachel P. avatar

    Rachel P.

  • Jennifer C. avatar

    Jennifer C.

Discover
  • Discover Early Phase Excellence
    82 (1)

    Early Phase Excellence

    Embark on the critical first steps of clinical discovery with our expertly managed early phase trials, where meticulous attention meets innovative strategy

    Explore
  • Discover Late Phase Success
    late-phase

    Late Phase Success

    Discover the path to market with our Late Phase Development expertise – delivering precision, scale, and efficiency for your clinical journey.

    Explore

Deep experience with debilitating disease and unique modalities

Like you, we understand that there’s a patient throughout the development pathway. Supporting our partners to bring innovative treatments to patients is our purpose. Leverage our experience in these therapeutic areas.

Specialized capabilities in every stage of clinical development

Leverage an integrated infrastructure that reduces the inefficiencies inherent in complex development. Integrate lab and trial execution to accelerate speed to market. Precision can customize and converge our capabilities to meet your program's unique needs—driving efficiency, agility, and success from start to finish.

  • Discover Explore
    clinical-trial-support

    Global CRO
    Services

    Award-winning CRO with deep oncology and rare disease expertise

    Explore
  • Discover Explore
    specialty-lab-services

    Global Laboratory
    Services

    Exceptional translational and biomarker sciences with global central lab services

    Explore